Assessing 3B Circumscribed Masses in Breast Cancer Screening
Author Information
Author(s): Farshid G, Downey P, Gill P G, Pieterse S
Primary Institution: Division of Tissue Pathology, Institute of Medical and Veterinary Science, BreastScreen SA
Hypothesis
Should the assessment of 3B lesions in breast cancer screening be discouraged due to the lack of established survival benefits?
Conclusion
The study supports the use of fine-needle aspiration biopsy for diagnosing 3B masses, as 8.3% of these lesions can be malignant.
Supporting Evidence
- 8.3% of 3B masses can be malignant, highlighting the need for careful assessment.
- The study found a recall rate of 6.7% for the first round of screening in South Australia.
- Fine-needle aspiration biopsy is recommended as a first-line diagnostic tool for 3B lesions.
Takeaway
Some lumps found during breast cancer screening can be cancerous, so it's important to check them carefully instead of ignoring them.
Methodology
The study utilized fine-needle aspiration biopsy and core biopsy to assess screen-detected 3B masses.
Limitations
The study does not provide definitive proof that detecting 3B masses reduces breast cancer mortality.
Participant Demographics
Participants included women with screen-detected 3B masses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website